Personalised Cancer Plan
Make treatment decisions with greater confidence
Precision insights that complement standard oncology care to guide next-step planning and ongoing monitoring.
It works alongside standard cancer care to support more informed discussions with your healthcare team.
Response Rates in a published Study1,2
In recurrent ovarian cancer, biomarker-guided treatment was associated with differences in response rates in a published study
matched
therapy
(matched) therapy
Median Progression-Free Survival (months)1,2
Biomarker-guided treatment was associated with differences in progression-free intervals in a published study
matched
therapy
(matched) therapy
1. Results observed in a published study. Individual outcomes may vary.
2. Source: Herzog TJ et al., Gynecologic Oncology, 2010.
Study in recurrent ovarian cancer evaluating biomarker-guided (matched) therapy versus non-matched approaches.
In a precision medicine–guided approach, diagnosis is combined with biological assessment, allowing doctors to monitor both imaging and biological signals. This can support more informed treatment planning and adjustments over time.
Are you starting your Chemo?
Get a free 15 min discussion with our expert
Empower yourself with knowledge about precision medicine!
Matched vs Non-Matched Therapy
Outcomes in a Published Study
Objective Response1,2
Rate (%)
Median Progression-1,2
Free Survival (months)
1. Results observed in a published study. Individual outcomes may vary.
2. Source: Herzog TJ et al., Gynecologic Oncology, 2010.
Study in recurrent ovarian cancer evaluating biomarker-guided (matched) therapy versus non-matched approaches.
- ✓ Detects genetic mutations
- ✓ Tracks tumour genetic evolution
- ✓ Useful for mutation monitoring over time
- ✕ Does not provide whole viable cancer cells
- ✓ Provides whole cancer cells for analysis
- ✓ Enables functional drug sensitivity testing
- ✓ Predicts survival across multiple solid tumours
- ✕ Not primarily used for detailed mutation tracking
Are you starting your Chemo?
Get a free 15 min discussion with our expert
Empower yourself with knowledge about precision medicine!
Monitoring Cancer Over Time
References
| # | Study | Year | Key Findings |
|---|---|---|---|
| 6 | Tsimberidou AM et al. Personalized medicine for patients with advanced cancer in phase I program at MD Anderson. | 2014 | Response 12% vs 5%; PFS 4 vs 2 months; OS 11 vs 9 months. |
| 7 | IMPACT Study – MD Anderson Precision Medicine Program. | 2017 | Matched therapy associated with improved response and survival outcomes. |
| 8 | UCSD Moores Cancer Center PREDICT Study. | 2016 | Stable disease or better 35% vs 16%; prolonged time without progression. |
| 9 | Real-world Molecular Tumor Board Data in Breast & Gynecologic Cancers. | 2022 | Response 31% vs 7%; reduced progression risk. |
| 10 | Herzog TJ et al. ChemoID-guided therapy in platinum-resistant ovarian cancer. | 2025 | ORR 55% vs 5%; PFS 11 vs 3 months (HR 0.27). |
| 11 | Tsimberidou AM et al. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT). JCO. | 2012 | Matched therapy improved response rates and survival compared to non-matched. |
| 12 | Von Hoff DD et al. Pilot study using molecular profiling to select therapy. JCO. | 2010 | Targeted treatment improved progression-free survival compared to prior therapy. |
| 13 | Alix-Panabières C, Pantel K. Clinical relevance of circulating tumor cells and ctDNA. Nat Rev Clin Oncol. | 2016 | CTCs predict survival across solid tumors; ctDNA useful for mutation tracking. |
| 14 | Pediatric MATCH Trial (National Cancer Institute). | 2020 | 2-year PFS 26% vs 12% in selected molecularly matched pediatric cases. |
| 15 | MD Anderson IMPACT Long-term Follow-up Analysis. | 2019 | Matched targeted therapy associated with improved overall survival. |
Contact Us
Contact Us for the updated information on Precision Medicine
+852 4750 3485
Email Us
info@mycancerinfo.org